Financial Performance - The company's operating revenue for Q3 2025 was ¥269,052,171.54, representing a year-on-year increase of 21.88%[4] - The total profit for the year-to-date period reached ¥160,973,765.52, showing a significant increase of 42.92% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2025 was ¥65,818,511.01, a decrease of 3.66% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2025 was ¥29,943,916.49, reflecting a substantial increase of 110.38% year-on-year[4] - The basic earnings per share for Q3 2025 was ¥0.16, down by 5.88% compared to the same period last year[5] - The company's net profit for the year-to-date period increased by 36.78% compared to the same period last year, driven by improved sales revenue and gross margin[10] - Total operating revenue for the first three quarters of 2025 reached ¥773,013,040.56, an increase of 19.0% compared to ¥649,434,483.19 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was ¥152,288,075.22, representing a 36.8% increase from ¥111,338,107.92 in 2024[19] - The total comprehensive income for the period attributable to the parent company was CNY 152,088,369.70, an increase from CNY 111,232,236.17 in the previous period, representing a growth of approximately 36.8%[20] - Basic and diluted earnings per share increased to CNY 0.38 from CNY 0.28, reflecting a growth of 35.7%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,520,143,731.40, an increase of 6.37% from the end of the previous year[5] - The company's total assets increased to ¥3,520,143,731.40 in 2025 from ¥3,309,304,222.53 in 2024, reflecting a growth of 6.4%[18] - Current liabilities rose to ¥452,646,555.31 in 2025, a significant increase of 54.8% compared to ¥292,538,489.37 in 2024[17] - The total liabilities of the company amounted to ¥474,400,099.30 in 2025, up from ¥315,934,369.88 in 2024, indicating a rise of 50.3%[17] - The company's equity attributable to shareholders increased to ¥3,045,743,632.10 in 2025 from ¥2,993,369,852.65 in 2024, marking a growth of 1.7%[18] Cash Flow and Investments - Cash and cash equivalents as of September 30, 2025, amount to RMB 339,211,526.39, an increase from RMB 215,882,035.67 on December 31, 2024[15] - Cash inflows from operating activities totaled CNY 758,153,089.72, up from CNY 655,908,841.07, indicating an increase of about 15.6%[21] - Net cash flow from operating activities was CNY 224,475,064.80, compared to CNY 189,967,018.99 in the previous year, marking a rise of approximately 18.2%[22] - Cash inflows from investment activities amounted to CNY 2,542,668,718.21, significantly higher than CNY 1,058,330,962.00, representing an increase of around 140.0%[22] - The net cash flow from investment activities was negative at CNY -86,038,564.66, an improvement from CNY -809,734,106.47 in the previous year[22] - Cash and cash equivalents at the end of the period were CNY 339,134,311.03, compared to CNY 177,807,241.29 at the end of the previous period, showing an increase of approximately 90.5%[23] - The company reported a net increase in cash and cash equivalents of CNY 123,329,490.72, contrasting with a decrease of CNY -739,448,161.22 in the previous year[22] Research and Development - Research and development expenses totaled ¥38,385,096.40 for Q3 2025, accounting for 14.27% of operating revenue, a decrease of 3.17 percentage points year-on-year[5] - Research and development expenses for the first three quarters of 2025 were ¥91,355,668.27, a decrease of 6.9% from ¥98,061,826.25 in 2024[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 26,515[12] - The largest shareholder, Yang Yong, holds 126,000,000 shares, representing 31.47% of total shares[12] - The second largest shareholder, Zhou Yan, holds 91,800,000 shares, representing 22.93% of total shares[12] - The company has a repurchase account holding 1,506,639 shares, accounting for 0.38% of total share capital[14] - The company has not reported any changes in the top 10 shareholders due to securities lending[14] - There are no known related party transactions among the other shareholders[14] Management and Governance - The company has not disclosed any significant operational updates for the reporting period[14] - The company has not applied new accounting standards or interpretations for the first time in 2025[24] - The company’s management team includes Yang Yong as the responsible person, Li Zhenhua as the head of accounting, and Sun Ling as the head of the accounting institution[20] Future Outlook - The company expects continued growth in revenue and gross margin as market conditions improve and product iterations expand[9]

炬芯科技股份有限公司 2025 年第三季度报告 证券代码：688049 证券简称：炬芯科技 炬芯科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 273,017,023.07 | 46.64 | 722,137,47 ...

深圳市朗科科技股份有限公司 2025 年第三季度报告 证券代码：300042 证券简称：朗科科技 公告编号：2025-056 深圳市朗科科技股份有限公司 2025 年第三季度报告 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入（元） | 315,919,531.07 | 82.73% | 794,830,981.56 | 35.19% | | 归属 ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥3,193,565,092.57, representing a year-on-year increase of 4.36%[5] - Total profit for the quarter was ¥558,116,474.65, showing a slight increase of 1.54% compared to the same period last year[5] - Net profit attributable to shareholders was ¥276,627,250.95, remaining stable with a year-on-year change of 0%[5] - The net profit after deducting non-recurring gains and losses was ¥273,992,594.16, a decrease of 0.53% year-on-year[5] - The basic earnings per share for the quarter was ¥0.10, unchanged from the previous year[5] - Total operating revenue for the first three quarters of 2025 reached ¥9,371,635,825.72, an increase of 4.35% compared to ¥8,981,673,151.73 in the same period of 2024[19] - Total operating costs for the first three quarters of 2025 were ¥8,041,346,527.11, up from ¥7,678,425,357.82 in 2024, reflecting a year-over-year increase of 4.73%[19] - Net profit for the first three quarters of 2025 was ¥1,177,480,725.34, a decrease of 11.55% from ¥1,331,850,405.45 in 2024[20] - Earnings attributable to shareholders of the parent company for the first three quarters of 2025 were ¥779,911,846.24, down 12.69% from ¥892,859,116.51 in 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.27, compared to ¥0.31 in the same period of 2024[22] - The company reported an operating profit of ¥1,550,459,097.53 for the first three quarters of 2025, slightly down from ¥1,634,524,842.12 in 2024[20] - Other comprehensive income after tax for the first three quarters of 2025 was ¥18,688,324.70, compared to ¥98,558,396.24 in 2024, showing a significant decline[20] - The total comprehensive income for the first three quarters of 2025 was ¥1,196,169,050.04, down from ¥1,430,408,801.69 in 2024[20] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥36,318,815,606.67, reflecting a 0.83% increase from the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 2.83% to ¥19,937,551,767.59 compared to the end of last year[5] - The company's total current assets increased to ¥8,867,446,209.84 from ¥7,776,859,790.36, reflecting a growth of approximately 14%[15] - Accounts receivable rose to ¥1,739,398,678.52, up from ¥1,597,272,811.12, indicating an increase of about 8.9%[15] - The total assets of the company reached ¥36,318,815,606.67, compared to ¥36,018,512,985.27 in the previous period, showing a slight increase of 0.83%[16] - The company's non-current assets decreased to ¥27,451,369,396.83 from ¥28,241,653,194.91, a decline of approximately 2.8%[16] - Short-term borrowings increased to ¥964,446,666.64 from ¥774,046,666.64, representing a rise of about 24.5%[16] - The total liabilities increased to ¥20,000,000,000, reflecting a growth of 5% compared to the previous period[16] - Total liabilities as of the end of the reporting period amounted to ¥8,983,240,499.48, a decrease from ¥9,502,956,035.16 at the end of the previous year[17] - Total equity increased to ¥27,335,575,107.19 from ¥26,515,556,950.11, indicating a growth of 3.09%[17] Cash Flow - The cash flow from operating activities for the year-to-date was ¥1,659,911,154.57, down 20.22% year-on-year[5] - In the first three quarters of 2025, the net cash flow from operating activities was CNY 1,659,911,154.57, a decrease of 20.2% compared to CNY 2,080,717,832.47 in the same period of 2024[24] - Total cash inflow from operating activities was CNY 9,304,404,900.98, slightly down from CNY 9,375,321,151.46 in the previous year[24] - Cash outflow for purchasing goods and services increased to CNY 5,322,622,805.84 from CNY 5,126,615,027.21, reflecting a rise of 3.8%[24] - The net cash flow from investment activities was CNY 197,150,605.33, recovering from a negative CNY 59,972,779.49 in the same period last year[25] - Cash inflow from investment activities totaled CNY 665,431,927.32, significantly higher than CNY 260,426,286.13 in the previous year[25] - Cash outflow for acquiring fixed assets and other long-term assets was CNY 468,281,321.99, up from CNY 320,399,065.62, indicating a 46.2% increase[25] - The net cash flow from financing activities was negative at CNY -902,656,380.04, an improvement from CNY -1,241,311,187.99 in the same period of 2024[25] - Total cash inflow from financing activities reached CNY 1,521,037,574.42, compared to CNY 1,000,700,000.00 in the previous year[25] - The ending balance of cash and cash equivalents was CNY 6,500,013,914.93, an increase from CNY 5,750,705,087.94 in the same period last year[25] Shareholding Structure - The total number of common shareholders at the end of the reporting period is 78,997[11] - The largest shareholder, Xianchuang Investment Co., Ltd., holds 1,644,213,619 shares, representing 56.81% of total shares[11] - The company has no significant changes in the shareholding structure or any new strategic initiatives reported during the conference call[12] Accounting Standards - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the year[26] Impairment Losses - The company reported a 36.75% increase in asset impairment losses, primarily due to a decrease in goodwill impairment losses[9] - Non-recurring gains and losses for the quarter totaled ¥2,634,656.79, with significant contributions from government subsidies[7]

Financial Performance - The company's operating revenue for the third quarter was ¥16,675,315.37, a decrease of 85.53% compared to the same period last year[5] - The total profit for the quarter was -¥141,626,892.20, with a year-to-date total profit of -¥364,875,621.08[5] - The net profit attributable to shareholders was -¥88,889,282.50 for the quarter, and -¥212,885,444.66 year-to-date[5] - The basic and diluted earnings per share for the quarter were both -¥0.68, with year-to-date figures at -¥1.64[6] - The weighted average return on equity was -171.28% for the quarter, a decrease of 169.02 percentage points year-to-date[6] - Total operating revenue for the first three quarters of 2025 was CNY 140,001,102.73, a decrease of 58.8% compared to CNY 339,546,991.50 in the same period of 2024[19] - Operating profit for the first three quarters of 2025 was a loss of CNY 248,529,602.12, compared to a loss of CNY 13,780,507.88 in the same period of 2024[19] - Total profit for the first three quarters of 2025 was a loss of CNY 364,875,621.08, significantly higher than a loss of CNY 14,247,544.56 in 2024[19] - The net profit for the first three quarters of 2025 was -342,056,732.91 CNY, compared to -13,245,399.93 CNY in the same period of 2024, indicating a significant decline in profitability[20] - The total comprehensive income for the period was -342,056,732.91 CNY, with -212,885,444.66 CNY attributable to the parent company's shareholders[20] - The company reported a basic and diluted earnings per share of -1.640 CNY for the current period, compared to -0.091 CNY in the same period of 2024[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥650,286,901.13, down 29.54% from the previous year[6] - Shareholders' equity attributable to the company was ¥8,688,320.86, reflecting a decrease of 90.86% compared to the previous year[6] - Total current assets decreased to CNY 321,132,040.14 from CNY 512,214,297.30 at the end of 2024, reflecting a decline of 37.2%[16] - Total non-current assets as of September 30, 2025, were CNY 329,154,860.99, down from CNY 410,766,343.80 at the end of 2024[16] - Total liabilities decreased to CNY 621,060,567.44 from CNY 678,165,438.32 at the end of 2024[17] - Shareholders' equity as of September 30, 2025, was CNY 29,226,333.69, a significant drop from CNY 244,815,202.78 at the end of 2024[17] Cash Flow - Cash and cash equivalents as of September 30, 2025, were CNY 14,316,023.01, down from CNY 40,276,044.56 at the end of 2024[16] - The operating cash flow for the first three quarters of 2025 was -32,552,402.01 CNY, a deterioration from -12,776,171.56 CNY in the same period of 2024[23] - Cash inflows from operating activities totaled 150,946,988.88 CNY, down from 354,687,870.93 CNY year-over-year[23] - Cash outflows from operating activities were 183,499,390.89 CNY, compared to 367,464,042.49 CNY in the previous year, reflecting a reduction in cash outflow[23] - The net cash flow from investing activities was -455,349.77 CNY, an improvement from -7,130,887.42 CNY in the same period of 2024[24] - The net cash flow from financing activities was 7,047,730.77 CNY, contrasting with -16,280,053.83 CNY in the previous year, indicating a positive shift in financing[24] - The ending cash and cash equivalents balance was 14,316,023.01 CNY, down from 22,430,843.50 CNY year-over-year[24] Operational Challenges - The company faced operational disruptions due to civil loan disputes and market fluctuations, impacting production and financial performance[10] - Non-recurring losses totaled -¥50,588,421.50 for the quarter, with year-to-date non-recurring losses at -¥99,440,034.98[7] - The company reported a significant increase in credit impairment losses, totaling CNY -40,378,181.75 for the first three quarters of 2025, compared to CNY -898,685.51 in the same period of 2024[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,489[12] Accounting Standards - The company has not applied new accounting standards for the current reporting period[25]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥122,396,636.14, representing a 50.58% increase year-over-year[5] - Net profit attributable to shareholders was ¥33,047,527.90, up 68.51% compared to the same period last year[5] - The basic earnings per share (EPS) for the quarter was ¥0.32, reflecting a 68.42% increase year-over-year[5] - The total profit for the period was ¥90,025,670.41, marking a 51.35% increase compared to the previous year[13] - The company’s net profit margin improved, with net profit for the year-to-date reaching ¥77,805,656.91, a 48.55% increase year-over-year[12] - Net profit for the period reached ¥77,805,656.91, a significant increase of 48.5% compared to ¥52,375,890.16 in the prior period[32] - Basic and diluted earnings per share improved to ¥0.76 from ¥0.51, indicating a positive trend in profitability[33] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,155,479,000.11, a 2.43% increase from the end of the previous year[5] - Total assets increased to ¥1,155,479,000.11, compared to ¥1,128,099,571.69 in the previous period, marking a growth of 2.4%[29] - Current assets totaled ¥845,504,456.10, slightly down from ¥845,585,757.44, indicating a marginal decrease of 0.01%[28] - Total liabilities rose to ¥146,926,449.85, compared to ¥127,871,367.04, reflecting a 14.5% increase[29] - The company's equity attributable to shareholders reached ¥1,008,552,550.26, up from ¥1,000,228,204.65, a growth of 0.2%[29] Cash Flow - The company reported a significant increase in cash flow from operating activities, with a net amount of ¥58,842,492.66, up 165.89%[5] - Net cash flow from operating activities was ¥58,842,492.66, up from ¥22,130,676.95 in the prior period, showcasing enhanced operational efficiency[36] - Cash inflow from operating activities totaled ¥336,158,053.89, compared to ¥267,777,127.33 in the previous year, marking a growth of approximately 25.5%[35] - Cash outflow for operating activities increased to ¥277,315,561.23 from ¥245,646,450.38, resulting in a net cash flow from operations of ¥58,842,492.66[36] - Investment activities generated a net cash flow of -¥45,212,891.91, slightly worse than -¥37,194,649.54 in the previous period, indicating ongoing investment expenditures[36] - The company reported cash and cash equivalents at the end of the period amounting to ¥499,130,516.80, down from ¥683,955,612.83 at the beginning of the period[37] - The company received cash from investment recoveries totaling ¥1,800,000,000.00, compared to ¥1,775,000,000.00 in the previous period, reflecting stable investment returns[36] - The company’s financing activities resulted in a net cash outflow of -¥72,458,505.53, consistent with the previous period's outflow of -¥72,353,974.46[36] Research and Development - Research and development expenses increased to ¥27,079,957.94, a rise of 46.01% year-over-year, indicating a focus on innovation[13] - Research and development expenses amounted to ¥27,079,957.94, up 46.1% from ¥18,546,761.11[31] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,782[17] - The top three shareholders hold the following percentages: Chen Zhisi 15.23%, Yao Zhengyuan 14.76%, and Zhang Jian 14.26%[17] - The top ten unrestricted shareholders include the National Social Security Fund with 1,506,104 shares, accounting for 1.46%[18] - The total number of shares held by the top ten unrestricted shareholders is 4,000,000 shares[18] - The company has a total of 0 preferred shareholders, indicating no preferred stock issuance[19] Share Repurchase - The company plans to repurchase shares with a total fund of no less than RMB 20 million and not exceeding RMB 40 million, with a maximum repurchase price adjusted to RMB 49.44 per share[22] - As of September 30, 2025, the company has repurchased a total of 677,049 shares, accounting for 0.66% of the total share capital[23] - The highest repurchase price was RMB 34.60 per share, and the lowest was RMB 29.86 per share[23] - The company has implemented a share repurchase plan in compliance with relevant laws and regulations[23] Business Changes - The company completed the registration of business changes on October 15, 2025, after adjusting its business scope and amending its articles of association[24] Financial Audit - The third quarter financial report was not audited, which may impact the reliability of the reported figures[38]

Financial Performance - The company's revenue for the third quarter was ¥1,180,696,726.26, a decrease of 7.89% compared to the same period last year[5] - Total profit for the quarter was ¥289,698,333.19, down 3.17% year-over-year[5] - Net profit attributable to shareholders was ¥67,882,704.06, an increase of 19.50% compared to the same period last year[5] - The basic earnings per share for the quarter was ¥0.30, reflecting an increase of 11.11% year-over-year[6] - Total operating revenue for the first three quarters of 2025 reached CNY 3,608,370,887.93, a slight increase from CNY 3,594,362,250.94 in the same period of 2024, representing a growth of approximately 0.39%[18] - Operating profit for the first three quarters of 2025 was CNY 853,803,442.06, compared to CNY 818,257,968.46 in 2024, indicating an increase of about 4.34%[19] - Net profit for the first three quarters of 2025 amounted to CNY 714,169,766.15, up from CNY 676,388,028.47 in 2024, reflecting a growth of approximately 5.57%[19] - Earnings per share for the first three quarters of 2025 were CNY 0.81, compared to CNY 0.71 in the same period of 2024, marking an increase of about 14.08%[20] - The company reported a total comprehensive income of CNY 714,268,914.78 for the first three quarters of 2025, compared to CNY 273,388,028.47 in 2024, showing a significant increase[19] Assets and Liabilities - Total assets at the end of the quarter were ¥6,901,163,172.64, a decrease of 3.57% from the end of the previous year[6] - Total current assets as of September 30, 2025, amount to ¥2,733,655,330.06, a decrease from ¥3,020,575,976.72 as of December 31, 2024[14] - Total non-current assets are valued at ¥4,167,507,842.58, slightly up from ¥4,136,403,900.60[15] - Total liabilities decreased to CNY 2,742,592,380.94 in 2025 from CNY 3,367,033,068.94 in 2024, a reduction of about 18.59%[16] - Total equity increased to CNY 4,158,570,791.70 in 2025 from CNY 3,789,946,808.38 in 2024, reflecting a growth of approximately 9.71%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥810,413,478.86, an increase of 14.80%[5] - Cash flow from operating activities for the first three quarters of 2025 was CNY 810,413,478.86, an increase from CNY 705,925,200.27 in 2024, representing a growth of approximately 14.81%[21] - Cash inflow from investment activities totaled $845.53 million, up from $482.21 million year-over-year[22] - Net cash flow from investment activities was $163.76 million, a significant improvement from a net outflow of $173.19 million in the previous period[22] - Cash inflow from financing activities reached $1.64 billion, compared to $1.54 billion in the prior year[22] - Net cash flow from financing activities was -$841.36 million, worsening from -$38.18 million year-over-year[22] - The ending balance of cash and cash equivalents was $1.27 billion, an increase from $1.04 billion at the end of the previous period[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,261[12] - The largest shareholder, Ningbo Jiuge Zhonglan Equity Investment Partnership, holds 26,655,691 shares, representing 10.34% of total shares[12] Investment and Development - The company reported a significant increase of 238.87% in trading financial assets due to increased investments in financial products[9] - The company plans to expand its market presence and enhance product development in the upcoming quarters[5] - The company has implemented strategies to improve financial performance, including reducing financial expenses by 40.19% through refinancing[10] - Research and development expenses for the first three quarters of 2025 were CNY 90,114,951.10, compared to CNY 86,771,947.67 in 2024, indicating an increase of about 2.93%[18] - The company has shown a consistent increase in investment income, reaching CNY 7,777,064.79 in 2025, compared to CNY 3,294,086.47 in 2024, which is an increase of approximately 136.00%[18]

Financial Performance - The company's operating revenue for Q3 2025 was ¥53,412,671.06, a decrease of 37.13% compared to the same period last year[4] - Net profit attributable to shareholders increased by 265.00% to ¥23,336,802.36 for the quarter, and 113.87% to ¥4,721,176.15 for the year-to-date[4] - Basic and diluted earnings per share rose by 266.67% to ¥0.15 for the quarter, and 113.64% to ¥0.03 for the year-to-date[4] - Total operating revenue for the current period is ¥145,483,823.20, a decrease of 24.4% compared to ¥192,600,713.02 in the previous period[28] - Net profit for the current period is ¥1,348,332.85, a significant improvement from a net loss of ¥50,961,052.83 in the previous period[29] - The company reported an operating profit of -¥3,526,096.46, an improvement from -¥36,459,540.35 in the previous period[29] - The company achieved a total comprehensive income of ¥1,493,621.16, a recovery from a loss of -¥50,848,504.62 in the previous period[29] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥23,842,662.12, an increase of 167.54%[4] - The net cash flow from investing activities was ¥16,350,007.26, an increase of 150.88% compared to the previous period[12] - Cash flow from operating activities generated a net cash inflow of ¥23,842,662.12, compared to a net outflow of -¥35,302,687.95 in the previous period[31] - Investment activities generated a net cash inflow of ¥16,350,007.26, compared to a net outflow of -¥32,131,354.83 in the previous period[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥804,605,828.97, a decrease of 9.03% from the end of the previous year[4] - The company's current assets totaled CNY 400,311,211.29, down from CNY 463,294,625.20, indicating a decrease of about 13.6%[25] - The company's total liabilities decreased to CNY 272,791,543.63 from CNY 376,746,323.94, representing a reduction of approximately 27.6%[26] - The company's cash and cash equivalents increased to CNY 110,468,154.01 from CNY 72,227,873.37, showing a growth of about 53.0%[25] - The company's accounts receivable decreased to CNY 80,521,647.49 from CNY 159,609,995.30, a decline of approximately 49.6%[25] - The company’s inventory decreased to CNY 186,543,102.44 from CNY 205,199,093.59, indicating a decline of approximately 9.0%[25] - The company’s long-term equity investments decreased to CNY 140,391,731.77 from CNY 177,109,749.70, a reduction of about 20.7%[25] - The company’s short-term borrowings decreased to CNY 50,030,444.44 from CNY 60,057,077.78, a decline of approximately 16.9%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,196[14] - The largest shareholder, Shanghai Feiyang Investment Management Co., Ltd., holds 25.41% of shares, totaling 39,909,935 shares[14] - The second-largest shareholder, Takeda Hiroshi, holds 10.97% of shares, totaling 17,225,262 shares[14] - The total number of restricted shares at the end of the period is 43,002,927, with 1,270,000 shares added during the period[17] - The company has approved a 2025 restricted stock incentive plan, which includes management and assessment measures[18] - The company plans to release 450,000 restricted shares under the 2025 incentive plan[17] - The shareholder Qian Chenglin has 9.30% of shares, totaling 14,611,247 shares, with 10,958,435 shares under pledge[14] - The company has a total of 41,732,927 restricted shares at the beginning of the period[17] - The shareholder Takeda Shuji holds 6.24% of shares, totaling 9,795,756 shares[14] - The company has not identified any related party relationships among the top ten shareholders, except for the Takeda brothers[14] - The company announced the completion of the first grant of restricted stock under the 2025 incentive plan, with the listing date set for July 3, 2025[21] Research and Development - The company's research and development expenses decreased by 61.25% to ¥7,660,147.00 compared to the previous period[12] - The company reported a substantial increase in government subsidies received, contributing to a rise in other income by 112.66% to ¥3,661,266.10[12] Costs - Total operating costs decreased to ¥172,082,030.50 from ¥195,785,132.97, reflecting a reduction of 12.1%[28] - The company incurred a financial expense of ¥3,900,351.80, up from ¥2,650,246.43 in the previous period, indicating increased borrowing costs[28]

Financial Performance - The company's operating revenue for Q3 2025 was approximately ¥9.88 billion, a decrease of 5.46% compared to the same period last year[6]. - The total profit for the quarter was approximately ¥1.12 billion, down 1.89% year-on-year, while the net profit attributable to shareholders increased by 4.52% to approximately ¥821.33 million[6][7]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was approximately ¥612.46 million, reflecting a year-on-year increase of 5.20%[9]. - Cash flow from operating activities for the quarter was approximately ¥1.25 billion, an increase of 15.57% compared to the same period last year[6]. - The basic and diluted earnings per share for the quarter were both ¥0.31, representing a year-on-year increase of 6.90%[6]. - For the first three quarters of 2025, the company achieved operating revenue of CNY 29.393 billion, a decrease compared to the same period last year[18]. - The net profit attributable to shareholders for the first three quarters of 2025 was CNY 2.523 billion, with a net profit of CNY 1.573 billion after deducting non-recurring gains and losses[18]. - Total operating revenue for the first three quarters of 2025 was CNY 29.39 billion, a decrease of 4.9% compared to CNY 30.91 billion in the same period of 2024[37]. - Net profit for the first three quarters of 2025 reached CNY 3.06 billion, an increase of 21.3% from CNY 2.52 billion in the first three quarters of 2024[37]. - Total comprehensive income for the period attributable to the parent company was CNY 2,242,462,807.32, an increase from CNY 1,833,394,697.38 in the same period last year, representing a growth of approximately 22.3%[38]. - Basic and diluted earnings per share increased to CNY 0.95 from CNY 0.75, reflecting a growth of 26.7% year-over-year[38]. Assets and Liabilities - The total assets of the company as of September 30, 2025, were approximately ¥118.12 billion, a slight increase of 0.56% from the end of the previous year[6]. - The equity attributable to shareholders was approximately ¥48.03 billion, up 1.62% from the end of the previous year[6]. - The company's total assets as of September 30, 2025, amounted to CNY 118.12 billion, slightly up from CNY 117.46 billion at the end of 2024[36]. - Total liabilities decreased to CNY 57.31 billion from CNY 57.53 billion year-over-year[36]. - The company’s long-term equity investments increased to CNY 26.38 billion from CNY 24.69 billion, reflecting a growth of 6.8%[36]. - The company’s total equity increased to CNY 60.81 billion from CNY 59.93 billion, indicating a growth of 1.5% year-over-year[36]. - Total liabilities increased to CNY 15,795,860,646.14 from CNY 14,947,230,943.39, representing an increase of approximately 5.7%[44]. - The total equity attributable to shareholders decreased to CNY 35,567,203,718.02 from CNY 35,728,698,458.71, a decline of about 0.45%[44]. Research and Development - Research and development expenses for the first three quarters of 2025 totaled CNY 2.730 billion, an increase of 3.08% year-on-year[19]. - The company’s total R&D investment for the first three quarters of 2025 was CNY 3.998 billion, reflecting a growth of 2.12% year-on-year[19]. - In Q3 2025, R&D expenses reached CNY 1.013 billion, marking a significant increase of 28.81% year-on-year[19]. - The company continues to focus on innovative drugs and high-end medical devices, aiming to optimize asset and financial structures through lean operations[18]. - The company’s innovative drug pipeline continues to expand, with multiple products in various stages of clinical trials and regulatory approvals[26]. - The company aims to enhance treatment options for patients with advanced cancers through its ongoing research and development efforts[21]. Shareholder Information - The controlling shareholder, Fosun High Technology, held a total of 961.424 million shares, accounting for approximately 36.00% of the total share capital at the end of the reporting period[16]. - The top ten shareholders collectively held 1.5 billion shares, with Fosun High Technology being the largest shareholder[15]. - The company completed the repurchase of 14,228,552 A shares, accounting for approximately 0.5328% of the total share capital, with a total repurchase amount of approximately RMB 348.36 million, at an average price of RMB 24.48 per share[30]. - The company repurchased 3,410,500 H shares, representing about 0.1277% of the total share capital, with a total repurchase amount of approximately HKD 47.84 million, at an average price of HKD 14.03 per share[31]. - The company approved an A-share stock option incentive plan, granting up to 5,726,100 A-share options, with the first grant not exceeding 4,580,900 options[33]. - The company approved an H-share restricted stock unit plan, granting up to 13,370,500 H-share restricted stock units, with the first grant not exceeding 10,696,400 units[34]. Regulatory Approvals and Product Development - The company received approval for a new indication of its innovative small molecule CDK4/6 inhibitor, FCN-437c, for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in China[21]. - The company’s HLX14 injection was approved by the FDA and the European Commission, covering all indications previously approved for the original product, making it the first domestically produced HLX14 to gain overseas approval[22]. - The company’s innovative PD-1 inhibitor, SRL-172, achieved its primary endpoint in a Phase III clinical study for gastric cancer, supporting early market application[23]. - The company established a nuclear medicine platform, Xingrui Jingxuan, to develop integrated diagnostic and therapeutic nuclear medicine products targeting the oncology field[24]. - The company submitted a registration application for FKC889 injection for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) in adults, which was accepted by the National Medical Products Administration in September 2025[22]. - The company’s HLX43 injection received orphan drug designation from the FDA for the treatment of thymic epithelial tumors, aiding its subsequent development and commercialization in the U.S.[23]. - The company is preparing clinical trials for Ga[68Ga]PSMA-0057 and Lu[177Lu]PSMA-0057 injections as part of its nuclear medicine product pipeline[24]. - The company has initiated clinical trials for HLX79, a treatment for active renal glomerulonephritis, and HLX43, targeting advanced non-small cell lung cancer (NSCLC) in the U.S.[28].

Revenue and Profitability - Revenue for Q3 2025 reached ¥164,399,742.15, an increase of 59.45% year-over-year[5] - Net profit attributable to shareholders decreased by 23.50% to ¥23,353,545.93 in Q3 2025[5] - Net profit excluding non-recurring items was ¥19,271,570.19, down 20.76% compared to the same period last year[5] - The company's operating revenue for the first three quarters of 2025 reached ¥434.70 million, a 32.47% increase compared to ¥328.16 million in the same period of 2024[10] - The net profit for the reporting period, excluding the impact of the newly acquired Foster Pharmaceuticals, was ¥36.76 million, reflecting a 20.43% year-on-year growth[10] - Net profit for the current period was ¥99,238,347.92, representing a 3.0% increase compared to ¥96,335,195.65 in the previous period[29] Assets and Liabilities - Total assets increased by 8.52% to ¥2,549,790,054.85 as of September 30, 2025[5] - The total liabilities increased to CNY 181,886,840.09 from CNY 71,162,838.83, indicating a significant rise of approximately 156.5%[24] - The company reported a total current assets of CNY 1,835,895,685.80 as of September 30, 2025, down from CNY 1,944,260,056.93 at the beginning of the period, representing a decrease of approximately 5.57%[22] - The total non-current assets increased to CNY 713,894,369.05 from CNY 405,359,118.69, showing an increase of approximately 76%[23] Cash Flow - Cash flow from operating activities showed a significant decline of 55.23%, totaling ¥47,723,128.59 year-to-date[5] - Cash inflow from operating activities totaled ¥393,575,655.90, compared to ¥368,404,311.40 in the previous period, reflecting a growth of 6.9%[31] - The net cash flow from operating activities was $47,723,128.59, a decrease of 55.3% compared to $106,599,489.96 in the previous period[32] - The total cash inflow from investment activities was $4,031,521,486.09, significantly up from $739,050,803.89, marking an increase of 445.5%[32] - The net cash flow from investment activities was $354,383,240.84, recovering from a negative cash flow of -$950,298,018.67 in the previous period[32] - The total cash inflow from financing activities was $79,601,100.00, compared to $11,500,000.00 in the previous period, representing an increase of 592.3%[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,024, with the largest shareholder holding 47.40% of the shares[13] - The company adjusted the grant price for the 2024 restricted stock incentive plan from CNY 22.30 per share to CNY 21.91 per share due to mid-year equity distribution[17] - The company plans to grant 179,000 shares of the second category of restricted stock to 13 eligible participants at the adjusted price of CNY 21.91 per share on July 2, 2025[17] Acquisitions and Goodwill - The company acquired a subsidiary, resulting in goodwill of ¥71,721,165.16[9] - The company completed the acquisition of 100% equity in Hangzhou Foster Pharmaceutical Co., Ltd., with the first phase of the equity transfer completed on July 9, 2025, resulting in the company holding 85% of the shares[19] - The company acquired Hangzhou Foster Pharmaceuticals in July 2025, which reported an operating revenue of ¥20.93 million and a net loss of ¥13.41 million during the reporting period[10] - The company's goodwill increased to CNY 71,721,165.16, reflecting the impact of recent acquisitions[23] Financial Performance Metrics - The weighted average return on equity decreased to 1.01%, down 0.36 percentage points from the previous year[5] - Basic earnings per share increased to ¥0.93 from ¥0.90, while diluted earnings per share rose to ¥0.92 from ¥0.89[30] - Total operating costs amounted to ¥336,820,135.14, up 47.4% from ¥228,599,500.59 year-over-year[28] - Research and development expenses were ¥30,612,903.47, up from ¥26,225,248.09, indicating a focus on innovation[28] Tax and Financial Charges - The company reported a significant increase in tax and additional charges by 82.77% to ¥4.67 million, primarily due to increased additional taxes[10] - The deferred income tax liabilities increased by 768.82% to ¥8.15 million, mainly due to the recognition of deferred taxes from the newly acquired assets of Foster Pharmaceuticals[10] Financial Adjustments - The financial expenses decreased by 67.06% to -¥8.20 million, attributed to adjustments in cash management product types[10] - The investment income surged by 975.39% to ¥12.61 million, due to changes in cash management product types[10] - The company reported a financial income of ¥12,832,185.57, down from ¥28,050,784.16, suggesting a decrease in interest income[28] Audit Information - The company did not undergo an audit for the third quarter financial report[34]